Pradaxa Clinical Trials This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

• News
• Research
• Blogs
• Podcasts
• Alerts
• Clinical Trials
• Forums

High Gastrointestinal Bleed Risk Outcomes in Patients With Non-valvular Atrial Fibrillation (NVAF) in France
Condition:   Atrial Fibrillation Interventions:   Drug: Apixaban;   Drug: Rivaroxaban;   Drug: Dabigatran;   Drug: Vitamin K antagonist (VKA) Sponsor:   Pfizer Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 9, 2021 Category: Research Source Type: clinical trials